

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **DIVERSITY OF BOARD MEMBERS NON-COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

Pursuant to Rule 13.92 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), The Stock Exchange of Hong Kong Limited will not consider diversity to be achieved for a single gender board. Following the resignation of Ms. Wu Guizhen as independent non-executive director of CSPC Pharmaceutical Group Limited (the “**Company**”) on 1 August 2022 as announced by the Company, the Company has a single gender board which does not meet the requirement under Rule 13.92 of the Listing Rules.

Since then, the Board has been actively identifying a suitable female candidate but requires more time to finalize an appropriate appointment. It is expected that the Board will appoint a suitable female candidate as director as soon as practicable and not later than 31 January 2023 in order to ensure compliance by the Company with the requirement under Rule 13.92 of the Listing Rules. Further announcement will be made by the Company as and when appropriate.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**LO Tai On**  
*Company Secretary*

Hong Kong, 28 October 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*